RWD119 Do Long-Acting Injectable Antipsychotics (LAIS) Lower Hospital Utilization and Deliver Superior Economic Outcomes in Schizophrenia (SCZ)? a Systematic Review of Real-World Evidence (RWE)

To review the available Real World Data (RWD) demonstrating comparative advantages of newer LAIs over oral antipsychotics (OAPs) in Schizophrenia with respect to relapse, hospitalization, and economic outcomes. A systematic literature (2000- present) was done by two reviewers searching Embase, PubMed/Medline, EBSCO, PsycINFO, ScienceDirect, Cochrane Library databases. Search terms screening criteria for article selection included LAI cost-effectiveness, antipsychotics, hospitalization/rehospitalization, benefits, LAIs. Selected articles were classified according type RWD sources used factors such as relapse frequency, LOS, SCZ-related & all-cause economic/humanistic outcomes measured. total 62 met study criteria, targeting three key measures: Studies (n=11) suggest when generation are utilized after first-episode, rates decrease significantly hospitalizations drop. The reported range reviewed studies varied between 16%-93%, depending on follow-up period (typically 1-2 years). Reduction hospitalization risk primarily assessed most via Odds Ratios (OR, a 19-53%) Relative Risk (RR) ratios, that widely. Many pre-post (n=19) modeling showed switch one-month paliperidone-palmitate (PP1M) cases delivered lower overall treatment costs (short-&long term), stronger net savings (relative pharmacy outpatient costs), mean inpatient costs, plan-level, per-patient costs. Superiority OAPs is evident their potential frequencies, ER visits, psychiatric LOS. However, RWE shows cost relative one another (newer versus older), older mostly limited. It also unclear whether benefits can outweigh higher prices.